NFKB1 and diabetes mellitus: Moreover, studies have shown that GLP-1R agonists may downregulate NF-κB activation in podocytes, glomerular endothelial cells, monocyte/macrophages, and mesangial cells, thereby inhibiting tge inflammatory response in diabetes models (32–35).